Deep Dive
Markets recover on earnings strength amid macro uncertainty
The S&P 500 and NASDAQ bounced back after sharp losses the previous week, with futures opening strongly across all segments. Nasdaq rose roughly 2% on this trading day as volatility muted to VIX levels around 17, briefly touching the 20s. Brian Strahan, managing director at Morgan Stanley with 38 years in the business dating back to the 1987 crash, argued that resilient corporate earnings combined with stable interest rates are the primary supports for equities. He emphasized that when corporate earnings are solid and rates hold steady, the market historically performs well. However, Strahan and Chief Investment Officer Megan Hornman both identified two key risks: interest rates and oil prices. Hornman added that the bond market may be mispricing inflation risk given continuing deficit pressures and lagged effects from the Strait of Hormuz closure. S&P 500 earnings estimates show 20% or more growth for every quarter through the rest of the year, though Hornman flagged this as overly optimistic given supply chain disruptions. Historically, midterm election years see a median 18% correction, suggesting current market positioning may not reflect that historical headwind.
Supreme Court protects Fed independence while empowering Trump elsewhere
The Supreme Court delivered two landmark rulings on presidential power that created a clear institutional distinction. By a 5-4 vote, the court rejected President Trump's attempt to fire Federal Reserve Governor Lisa Cook on claims of mortgage fraud, establishing that Fed members serve 14-year terms with strong protection against removal without proper due process. Cook had refused to bow to political pressure, and the court ruled she was entitled to explanation of evidence and an avenue to respond. In her statement, Cook celebrated the affirmation that the Fed must make policy decisions guided by evidence and independent judgment free from political interference. However, the court simultaneously ruled 6-3 in Trump v. Slaughter that the president retains broad authority to remove commissioners of other independent agencies like the FTC, effectively upholding the firing of FTC Commissioner Rebecca Slaughter. Trump indicated he would pursue alternative approaches to address concerns, signaling his administration won't let the Cook ruling stop regulatory agendas. The rulings codified a hierarchy where the Federal Reserve receives heightened insulation from political control, while other regulatory bodies remain more vulnerable to presidential removal.
Options market explodes to record volumes as retail dominates trading
Options volume reached unprecedented levels, averaging over 70 million contracts daily in June compared to 18-19 million in 2019 — a 3.7x increase. The sector is on pace for a record year, with S&P 500 daily options alone generating roughly $18 billion in daily premium. Two-thirds of S&P options activity involves zero DTE contracts (those expiring the same day they trade), amounting to approximately 3 million contracts daily. This shift reflects commission compression during COVID, retail investor education through peer communities, and dramatically lower barriers to entry. Analysts attributed the surge to commission-free trading, improved brokerage tools enabling algorithmic execution at predictable intervals, and FOMO following missed IPO allocations like SpaceX's secondary debut. SpaceX options set a record 1.8 million contracts on day one of trading, surpassing Meta's previous record, as the stock briefly reached $220 and momentarily surpassed Amazon in market cap. Despite explosive retail activity, analysts noted that covered calls and vertical spreads represent appropriate entry strategies for managing risk. One analyst with 35 years in the business observed that if you own appreciated stock you can understand selling a call, while vertical spreads provide limited-risk income strategies. The market remains very efficient and liquid, though the concentration in same-day expirations raises questions about position sizing discipline.
Microsoft weakness signals tech valuation pressure and AI competition fears
Microsoft experienced its worst month since 2000, with the stock trudging lower and lower despite otherwise bullish option flow showing customers buying calls and selling puts. The options positioning suggested conviction about undervaluation, yet price action revealed deeper market concerns not being alleviated by call buyers. Analysts attributed the weakness to competitive anxieties in the AI and data center race rather than options market signals. The weakness came as investors questioned how Microsoft would compete against rivals in increasingly capital-intensive AI infrastructure buildouts. Strahan pushed back against market commentators like Jeremy Grantham making extreme predictions of 70% market corrections based on AI bubble theories, arguing such calls lacked grounding in reality. Nike reported earnings after close with options suggesting an 8% move; the stock had fallen from around $70 a year ago to $41, down 5 of the last 6 days with notable put activity at the 38 strike. Hornman recommended that tech investors take profits on large gains and rotate toward lagging small and mid-cap value stocks, noting that AI capex spending continues climbing while free cash flow declines substantially — suggesting the market may be approaching a reckoning on AI monetization.
Nuclear renaissance and utility sector face financing and regulatory headwinds
The Department of Energy announced $17.5 billion in loan support targeting deployment of 10 nuclear reactors across the US. However, analyst Anthony Crodell noted these funds would likely flow to newer nuclear developers rather than traditional utilities, as utility investors explicitly want to avoid nuclear development after historical cost overruns. The Southern Company's Vogel nuclear project ran from 2010 to 2024 — 14 years instead of the planned 7 — and bankrupted major contractors Westinghouse and Chicago Bridge and Iron. For a nuclear renaissance to succeed, Crodell argued that government entities like TVA or state power authorities must put their balance sheets on the line for cost overruns, or hyperscale tech companies must commit capital — neither has happened at scale. The utility sector underperformed in 2026 despite strong earnings fundamentals, driven by political and regulatory pressure around affordability. Pennsylvania Governor Shapiro's letter about lower returns and equity ratio changes sparked the selling, and with 36 gubernatorial elections this year, Crodell expects utilities to become campaign fodder despite bills being historically low as a percentage of consumer wallet. Yet data center demand continues driving utility earnings upside through rate base growth, suggesting long-term fundamentals remain healthy despite near-term regulatory uncertainty.
Peptide market emerges as telehealth opportunity amid regulatory uncertainty
The peptide market emerged as a significant telehealth opportunity riding wellness and health-maximization trends, with BPC157 identified as one of the most popular options. Hims and Herds positioned itself as the easy beneficiary play given existing telehealth infrastructure, starting with hair loss and erectile dysfunction before expanding into dermatology, weight loss, hormone replacement, and testosterone replacement therapy. RFK Jr.'s appointment as Department of Health and Human Services head signaled potential regulatory support, with the official having publicly endorsed some peptides used in the health-maximization craze. Peptides occupy a gray area between pharmaceuticals and supplements, with supply chains running through alternative compounding pharmacies at varying legal and licensing levels. Pricing is expected to follow GLP-1 telehealth models in the $150-$250 range for approved peptides. However, an FDA advisory committee meeting scheduled for July 23-24 will determine approval pathways, with safety validation critical to market success. Without positive FDA recommendations, the gray market status quo would persist. Analyst Michael Churnney noted there is solid scientific backing for many peptides, though not always from formal clinical trials, and emphasized that the biggest risk is whether the market prices in potential regulatory headwinds over the coming months.